3M CO
For the period ended Dec 31, 2024. Filed Feb 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 5, 2025
MMM$188.63+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
FORM 10-K
For the Year Ended December 31, 2024
| TABLE OF CONTENTS | PAGE |
|---|---|
| PART I | 4 |
| Item 1. Business | 4 |
| Item 1A. Risk Factors | 10 |
| Item 1B. Unresolved Staff Comments | 17 |
| Item 1C. Cybersecurity | 17 |
| Item 2. Properties | 18 |
| Item 3. Legal Proceedings | 18 |
| Item 4. Mine Safety Disclosures | 18 |
| PART II | 18 |
| Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 18 |
| Item 6. [Reserved] | 19 |
| Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 19 |
| Overview | 19 |
| Results of Operations | 28 |
| Performance by Business Segment | 30 |
| Performance by Geographic Area | 35 |
| Critical Accounting Estimates | 35 |
| New Accounting Pronouncements | 37 |
| Financial Condition and Liquidity | 37 |
| Financial Instruments | 40 |
| Item 7A. Quantitative and Qualitative Disclosures About Market Risk | 40 |
| Item 8. Financial Statements and Supplementary Data | 41 |
| Index to Financial Statements | 41 |
| Management’s Responsibility for Financial Reporting | 41 |
| Management’s Report on Internal Control Over Financial Reporting | 41 |
| Report of Independent Registered Public Accounting Firm | 42 |
| Consolidated Statement of Income (Loss) | 45 |
| Consolidated Statement of Comprehensive Income (Loss) | 46 |
| Consolidated Balance Sheet | 47 |
| Consolidated Statement of Changes in Equity | 48 |
| Consolidated Statement of Cash Flows | 49 |
| Notes to Consolidated Financial Statements | 50 |
| NOTE 1. Significant Accounting Policies | 50 |
| NOTE 2. Discontinued Operations | 54 |
| NOTE 3. Revenue | 56 |
| NOTE 4. Divestitures | 56 |
| NOTE 5. Goodwill and Intangible Assets | 57 |
| NOTE 6. Restructuring Actions | 59 |
| NOTE 7. Supplemental Income (Loss) Statement Information | 60 |
| NOTE 8. Supplemental Balance Sheet Information | 61 |
| NOTE 9. Supplemental Equity and Comprehensive Income (Loss) Information | 62 |
| NOTE 10. Supplemental Cash Flow Information | 63 |
| NOTE 11. Income Taxes | 63 |
| NOTE 12. Earnings (Loss) Per Share | 66 |
| NOTE 13. Marketable Securities | 67 |
| NOTE 14. Long-Term Debt and Short-Term Borrowings | 68 |
| NOTE 15. Pension and Postretirement Benefit Plans | 70 |
| NOTE 16. Supplier Finance Program Obligations | 77 |
| TABLE OF CONTENTS | PAGE |
|---|---|
| NOTE 17. Derivatives | 77 |
| NOTE 18. Fair Value Measurements | 81 |
| NOTE 19. Commitments and Contingencies | 83 |
| NOTE 20. Leases | 105 |
| NOTE 21. Stock-Based Compensation | 106 |
| NOTE 22. Business Segments and Geographic Information | 109 |
| NOTE 23. Quarterly Data (Unaudited) | 113 |
| Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure | 114 |
| Item 9A. Controls and Procedures | 114 |
| Item 9B. Other Information | 114 |
| Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 114 |
| PART III | 115 |
| Item 10. Directors, Executive Officers and Corporate Governance | 115 |
| Item 11. Executive Compensation | 115 |
| Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 116 |
| Item 13. Certain Relationships and Related Transactions, and Director Independence | 116 |
| Item 14. Principal Accounting Fees and Services | 116 |
| PART IV | 117 |
| Item 15. Exhibits, Financial Statement Schedules | 117 |
ANNUAL REPORT ON FORM 10-K
For the Year Ended December 31, 2024
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.